Dechra Pharmaceuticals PLC Dechra acquires worldwide rights to verdinexor (9957X)
January 11 2022 - 2:00AM
UK Regulatory
TIDMDPH
RNS Number : 9957X
Dechra Pharmaceuticals PLC
11 January 2022
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED
UNDER THE MARKET ABUSE REGULATION (EU) NO.596/2014.
Tuesday, 11 January 2022
Dechra(R) Pharmaceuticals PLC
(Dechra, Group, Company)
Acquisition
Dechra acquires the worldwide rights to verdinexor for dogs
The Board of Dechra is pleased to announce that it has agreed
terms with Anivive Lifesciences, Inc to acquire the worldwide
rights to verdinexor, a novel treatment of all forms and stages of
canine lymphoma in dogs. Under the terms of the agreement Dechra
will acquire the global product rights and a first right of refusal
for other species along with the trademark (Laverdia(R)).
The product, currently sold as LAVERDIA-CA1 in the USA is a
novel oral SINE (selective inhibitor of nuclear export) drug and
the first oral tablet for canine lymphoma. It was conditionally
approved by the FDA Center for Veterinary Medicine on 11 January
2021. Dechra will acquire the worldwide marketing rights, the
rights to the intellectual property, the marketing authorisations
(when granted) and associated regulatory documentation, supply
contracts with third parties in relation to the raw material and
manufacture of the finished product. No other assets are being
transferred to Dechra.
Sales of the product in the USA commenced under the conditional
approval in July 2021. Full dossier submissions are planned for
USA, UK, EU, Brazil, Australia, Japan and Canada.
Ian Page, Dechra's Chief Executive Officer commented:
"We are delighted to acquire the worldwide rights to Laverdia.
Its addition to our portfolio will expand Dechra into a new, niche
therapy area, while also offering veterinarians and dog owners a
simple to use, effective medication for lymphoma that extends the
time a family has with their pet."
Enquiries:
Dechra Pharmaceuticals PLC Office: +44 (0) 1606 814
730
Ian Page, Chief Executive Officer
Paul Sandland, Chief Financial Officer
e-mail: corporate.enquiries@dechra.com
TooleyStreet Communications Ltd Mobile: +44 (0) 7785 703
523
Fiona Tooley, Director
e-mail: fiona@tooleystreet.com
About Dechra
Dechra is global specialist veterinary pharmaceuticals and
related products business. Our expertise is in the development,
manufacture and sales and marketing of high quality products
exclusively for veterinarians worldwide. Dechra's business is
unique as the majority of its products are used to treat medical
conditions for which there is no other effective solution or have a
clinical or dosing advantage over competitor products.
For more information, please visit: www.dechra.com .
Stock Code: Full Listing (Pharmaceuticals): DPH
LEI: 213800J4UVB5OWG8VX82
About Laverdia
LAVERDIA-CA1 is a new oral treatment option for canine lymphoma.
It is the first small-molecule selective inhibitor of nuclear
export (SINE) drug specifically designed for veterinarian use. It
employs a novel targeted mechanism of action where it targets and
binds to Exportin 1 (XPO1)-a "transport" protein that proliferates
in certain types of cancer. Excessive amounts of XPO1 export
important tumour suppressing proteins (TSPs)-necessary for fighting
cancer-from the nuclei of cells, rendering them vulnerable to
uncontrolled growth. With its targeted blocking of XPO1,
LAVERDIA-CA1 allows for TSPs to be trapped inside the cell nucleus,
triggering programmed cell death of lymphoma cells while sparing
healthy cells.
About Anivive Lifesciences, Inc
Anivive Lifesciences, Inc, a US-based company, is a
next-generation pet health drug discovery and commercialization
company that dramatically improves the speed and cost of addressing
unmet medical needs in pets. Using a novel technology and analytics
platform, Anivive discovers first-in-class therapeutics for unmet
conditions in pets.
For more information, please visit: www.anivive.com .
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of
Dechra Pharmaceuticals PLC.
Forward Looking Statement
This document may contain certain forward-looking statements.
The forward-looking statements reflect the knowledge and
information available to the Company during the preparation and up
to the publication of this document. By their very nature, these
statements depend upon circumstances and relate to events that may
occur in the future thereby involve a degree of uncertainty.
Therefore, nothing in this document should be construed as a profit
forecast by the Company.
Market Abuse Regulation (MAR)
The information contained within this announcement may contain
inside information stipulated under the Market Abuse (Amendment)
(EU Exit) Regulations 2018. Upon the publication of this
announcement via the Regulatory Information Service, this inside
information is now considered to be in the public domain.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ACQGZGMMGGVGZZZ
(END) Dow Jones Newswires
January 11, 2022 02:00 ET (07:00 GMT)
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From Apr 2024 to May 2024
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From May 2023 to May 2024